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Background
IL-15 activates and induces the proliferation of CD8+
T cells and NK cells. ALT-803 (Altor Bioscience, Miramar,
FL) is a superagonist of IL-15 consisting of 2 molecules of
IL-15 N-to-D substituted at position 72, bound to 2 mole-
cules of the “sushi” domain of IL-15 alpha receptor and a
single Fc fragment of IgG1. ALT-803 has been shown to
exert superior antitumor activity and possess a longer
half-life compared with unmodified IL-15 in animal mod-
els of myeloma, melanoma and bladder cancer. The Can-
cer Immunotherapy Trials Network (CITN) has initiated a
Phase I/expansion trial of weekly intravenous (i.v.)
ALT-803 in patients (pts) with advanced melanoma (mel).
The primary objectives are to identify a maximum toler-
ated dose (MTD)/minimum effective dose (MED), defined
by toxicities and by lymphocyte and leukocyte expansion,
respectively. A cohort of 12 pts will then receive Rx at the
MTD or MED (whichever is lower) to further analyze
immune responses and screen for antitumor activity. The
overall goal is to develop a regimen that can be combined
with immune checkpoint blockade, co-stimulatory mole-
cules, adoptive T cell therapy, tumor vaccine or intrale-
sional Rx.
Methods
Dose escalation will be conducted by treating 1 pt each
at the first 2 dose levels (0.3 and 0.5 mcg/kg weekly)
followed by 3 or 6 pts at each of the higher dose levels
(1, 3, 6 mcg/kg) until MTD or MED is reached. Each
cycle consists of 4 weekly i.v. bolus infusions followed
by 2 weeks’ observation. Pts receive the first dose as
inpatients for close hemodynamic monitoring and sub-
sequent Rx in the outpatient setting. The absolute lym-
phocyte count and other laboratory and clinical
parameters are evaluated weekly, and flow cytometric
enumeration and functional analyses of T and NK cell
subsets are done pre-treatment (Rx) and weekly.
Results
To date, 2 pts have initiated Rx. The first pt, unmedicated
for the first dose, experienced fever and rigor but no
hemodynamic effects after the first dose and no further
side effects after doses 2-4. The second pt, premedicated
with acetaminophen, received the first dose with no side
effects. Data regarding the peripheral blood T and NK
cell responses to Rx will be presented. Pt accrual to dose
level 3 will begin in August, 2014.
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